Potato chip recall upgraded to highest FDA risk level over salmonella concerns
The FDA has classified a massive recall of Utz potato chip brands as a Class I risk due to potential salmonella contamination.
Velocity timeline
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Utz has issued a voluntary recall of certain limited varieties of Zapp’s and Dirty Potato Chips. The FDA has upgraded the recall to the highest risk level, known as Class I, because of salmonella concerns.
Coverage from WSB-TV and The Healthy reports that the recall affects 684,000 bags. WRNJ Radio notes that the recall includes products sold in New Jersey, while ABC11 News and WGCU focus on the risk level and the specific brands involved.
Monitoring will focus on the distribution of the 684,000 bags and further updates regarding the limited varieties affected by the salmonella concerns.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 1h ago.
Quick answers
Which potato chip brands are affected?
The recall involves certain limited varieties of Zapp’s and Dirty Potato Chips.
How many bags are included in the recall?
According to coverage from WSB-TV and The Healthy, 684,000 bags are affected.
Why was the risk level upgraded?
The recall was upgraded to Class I, the highest FDA risk level, due to salmonella concerns.
Coverage (5)
- Utz issues voluntary recall of certain limited varieties of Zapp’s and Dirty Potato Chips WGCU · 23h ago
- Potato Chip Recall: Highest FDA Warning for 684,000 Bags The Healthy @Reader's Digest · 23h ago
- Recall alert: 684K bags of Zapps, Dirty chips recalled; classified as Class I WSB-TV · 23h ago
- FDA classifies recall of Utz potato chips sold in New Jersey as highest risk WRNJ Radio · 23h ago
- Potato chip recall upgraded to highest FDA risk level over salmonella concerns ABC11 News · 23h ago broke it first
People, places & organizations
Topics
Related trends
New Drugs Are Replacing Chemo for Aggressive Breast Cancer
The FDA has granted broad first-line approval for Gilead's Trodelvy, signaling a shift away from traditional chemotherapy for aggressive breast cancer.
The Wearable Data Your Doctor Actually Wants
Wearable technology is shifting from general fitness tracking toward clinical healthcare integration and Medicare eligibility.
HHS Launches Unprecedented Department-Wide Effort to Restore American Leadership in Clinical Trials
The U.S. Department of Health and Human Services is launching a department-wide effort to accelerate clinical trials and restore American leadership in medical research.